Imugene Management
Management criteria checks 1/4
Imugene's CEO is Leslie Chong, appointed in Nov 2016, has a tenure of 7.42 years. total yearly compensation is A$2.48M, comprised of 30.2% salary and 69.8% bonuses, including company stock and options. directly owns 1.09% of the company’s shares, worth A$6.63M. The average tenure of the management team and the board of directors is 1.1 years and 5.6 years respectively.
Key information
Leslie Chong
Chief executive officer
AU$2.5m
Total compensation
CEO salary percentage | 30.2% |
CEO tenure | 7.4yrs |
CEO ownership | 1.1% |
Management average tenure | 1.1yrs |
Board average tenure | 5.6yrs |
Recent management updates
Recent updates
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Sep 19We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
May 30Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Jan 30Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More
Nov 11Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Aug 22Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Feb 28A Look At Imugene's (ASX:IMU) CEO Remuneration
Feb 17Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years
Dec 24CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -AU$89m |
Sep 30 2023 | n/a | n/a | -AU$64m |
Jun 30 2023 | AU$2m | AU$750k | -AU$38m |
Mar 31 2023 | n/a | n/a | -AU$39m |
Dec 31 2022 | n/a | n/a | -AU$40m |
Sep 30 2022 | n/a | n/a | -AU$39m |
Jun 30 2022 | AU$1m | AU$600k | -AU$38m |
Mar 31 2022 | n/a | n/a | -AU$33m |
Dec 31 2021 | n/a | n/a | -AU$27m |
Sep 30 2021 | n/a | n/a | -AU$23m |
Jun 30 2021 | AU$789k | AU$408k | -AU$18m |
Mar 31 2021 | n/a | n/a | -AU$15m |
Dec 31 2020 | n/a | n/a | -AU$12m |
Sep 30 2020 | n/a | n/a | -AU$11m |
Jun 30 2020 | AU$733k | AU$375k | -AU$11m |
Mar 31 2020 | n/a | n/a | -AU$10m |
Dec 31 2019 | n/a | n/a | -AU$9m |
Sep 30 2019 | n/a | n/a | -AU$8m |
Jun 30 2019 | AU$777k | AU$350k | -AU$8m |
Mar 31 2019 | n/a | n/a | -AU$7m |
Dec 31 2018 | n/a | n/a | -AU$6m |
Sep 30 2018 | n/a | n/a | -AU$5m |
Jun 30 2018 | AU$403k | AU$300k | -AU$4m |
Mar 31 2018 | n/a | n/a | -AU$3m |
Dec 31 2017 | n/a | n/a | -AU$3m |
Sep 30 2017 | n/a | n/a | -AU$3m |
Jun 30 2017 | AU$337k | AU$290k | -AU$3m |
Compensation vs Market: Leslie's total compensation ($USD1.59M) is above average for companies of similar size in the Australian market ($USD752.00K).
Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.
CEO
Leslie Chong
7.4yrs
Tenure
AU$2,482,687
Compensation
Ms. Leslie Chong served as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020 until July 2023. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 11.5yrs | AU$515.23k | 5.77% A$ 35.0m | |
CEO, MD & Executive Director | 7.4yrs | AU$2.48m | 1.09% A$ 6.6m | |
CFO & Company Secretary | 1.6yrs | AU$839.00k | no data | |
Head of Corporate Development | less than a year | AU$874.91k | 0.24% A$ 1.5m | |
Chief Business Officer | 2.8yrs | AU$799.20k | no data | |
Chief Operating Officer | less than a year | no data | no data | |
Senior Vice President of Clinical Operations | 2.3yrs | no data | no data | |
Senior Vice President of Clinical Development | less than a year | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
1.1yrs
Average Tenure
57yo
Average Age
Experienced Management: IMU's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 11.5yrs | AU$515.23k | 5.77% A$ 35.0m | |
CEO, MD & Executive Director | 6.1yrs | AU$2.48m | 1.09% A$ 6.6m | |
Independent Non-Executive Director | 4.9yrs | AU$115.52k | 0.28% A$ 1.7m | |
Non-Executive Director | less than a year | AU$2.08k | 0.0016% A$ 9.9k | |
Chair of Oncolytic Virotherapy Scientific Advisory Board | 4.4yrs | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | 10yrs | no data | no data | |
Member of Scientific Advisory Board | 5.5yrs | no data | no data | |
Scientific Advisory Board Member | 8yrs | no data | no data | |
Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
Member of Scientific Advisory Board | 5.6yrs | no data | no data | |
Member of Scientific Advisory Board | 5.5yrs | no data | no data |
5.6yrs
Average Tenure
Experienced Board: IMU's board of directors are considered experienced (5.6 years average tenure).